Rhumbline Advisers Bei Gene, Ltd. Transaction History
Rhumbline Advisers
- $105 Billion
- Q2 2024
A detailed history of Rhumbline Advisers transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Rhumbline Advisers holds 1,951 shares of BGNE stock, worth $455,831. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,951
Previous 2,101
7.14%
Holding current value
$455,831
Previous $328,000
15.24%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding BGNE
# of Institutions
213Shares Held
45.1MCall Options Held
106KPut Options Held
93.1K-
Baker Bros. Advisors LP New York, NY10.6MShares$2.47 Billion20.04% of portfolio
-
Capital International Investors Los Angeles, CA7.01MShares$1.64 Billion0.21% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$1.21 Billion19.1% of portfolio
-
Primecap Management CO Pasadena, CA4.99MShares$1.16 Billion0.52% of portfolio
-
Baillie Gifford & CO3.68MShares$860 Million0.42% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $24.2B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...